Accueil › Myélome multiple › Colorado › Denver
Essais cliniques pour Myélome multiple à Denver, CO
26 études pour Myélome multiple recherchent des participants dans et autour de Denver (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Recrutement en coursPhase 1
- Colorado Blood Cancer Institute /ID# 280275, Denver
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Recrutement en coursPhase 3
- Research Site, Denver
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Recrutement en coursPhase 1
- Colorado Blood Cancer Institute, Denver
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Recrutement en coursPhase 1
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 3
- Colorado Blood Cancer Institute, Denver
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Recrutement en coursPhase 2
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 3
- Colorado Blood Cancer Institute, Denver
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Recrutement en coursPhase 1
- Research Site, Denver
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Recrutement en coursPhase 2/3
- Colorado Blood Cancer Institute /ID# 279080, Denver
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Recrutement en coursPhase 3
- CBCI, Colorado Blood Cancer Institute, Denver
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 2
- Colorado Blood Cancer Institute, Denver
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Recrutement en coursPhase 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1/2
- Research Site, Denver
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Recrutement en coursPhase 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Recrutement en coursPhase 1/2
- Research Site, Denver
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Recrutement en coursPhase 3
- Research Site, Denver
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Recrutement en coursPhase 1/2
- Colorado Blood Cancer Institute /ID# 273129, Denver
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Recrutement en coursPhase 2
- Colorado Blood Cancer Institute, Denver
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Recrutement en coursPhase 3
- Colorado Blood Cancer Institute, Denver
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Recrutement en coursPhase 2
- Colorado Blood Cancer Institute, Denver
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Recrutement en coursPhase 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Colorado Blood Cancer Institute /ID# 273751, Denver
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Recrutement en coursPhase 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Recrutement en coursPhase 1/2
- Colorado Blood Cancer Institute, Denver
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Colorado Blood Cancer Institute, Denver
Essais pour Myélome multiple dans d'autres villes
- New York City, NY60 études
- Boston, MA42 études
- Atlanta, GA41 études
- Houston, TX38 études
- Durham, NC37 études
- Nashville, TN32 études
- Columbus, OH24 études
- Rochester, MN24 études
- Baldwin Park, CA23 études
- St. Louis, MO23 études
- Chicago, IL22 études
- Washington, DC22 études
Autres études à Denver
- Cancer métastatique29 études
- Cancer du sein28 études
- Cancer du poumon non à petites cellules27 études
- Cancer colorectal23 études
- Cancer (tous types)19 études
- Mélanome19 études
- Cancer de la prostate19 études
- Cancer de l'ovaire16 études
- Cancer de l'endomètre16 études
- Cancer du poumon16 études
- Lymphome non hodgkinien14 études
- Cancer du pancréas13 études
Source : ClinicalTrials.gov, données récupérées le 1 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.